Overview

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

Status:
Terminated

Trial end date:
2016-11-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA), diagnosed within 6 months and inadequately controlled by MTX alone.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Adalimumab
Folic Acid
Methotrexate
Vitamin B Complex